2018
A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma
Foss FM, Parker T. A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma. The Oncologist 2018, 23: 397-e30. PMID: 29438091, PMCID: PMC5896711, DOI: 10.1634/theoncologist.2017-0658.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaNon-Hodgkin lymphomaOverall response rateIntermediate-grade B-cellB cellsPartial responseResponse ratePhase I dose-escalation studyRefractory acute lymphoblastic leukemiaI dose-escalation studyT-cell non-Hodgkin lymphomaB-cell non-Hodgkin lymphomaPositron emission tomography scanSecond-generation purine nucleoside analogAggressive B-cell lymphomasPhase IDose of clofarabineGrade 3 leukopeniaLow-dose cohortMinimal hematologic toxicityRefractory acute leukemiaRefractory low gradeRefractory lymphoid malignanciesSingle-agent rituximab
2012
Genetic polymorphisms in IL10RA and TNF modify the association between blood transfusion and risk of non‐Hodgkin lymphoma
Bi X, Zheng T, Lan Q, Xu Z, Chen Y, Zhu G, Foss F, Kim C, Dai M, Zhao P, Holford T, Leaderer B, Boyle P, Deng Q, Chanock SJ, Rothman N, Zhang Y. Genetic polymorphisms in IL10RA and TNF modify the association between blood transfusion and risk of non‐Hodgkin lymphoma. American Journal Of Hematology 2012, 87: 766-769. PMID: 22649007, PMCID: PMC3576861, DOI: 10.1002/ajh.23244.Peer-Reviewed Original ResearchConceptsNon-Hodgkin lymphomaAG/AA genotypesHistory of transfusionBlood transfusionB-cell lymphomaGG genotypeAA genotypePopulation-based case-control studyRisk of NHLGenetic polymorphismsT-cell lymphomaCase-control studyDecreased riskNHL overallIL10RA geneConnecticut womenNHL riskTh2 cytokine genesTransfusionLymphomaCytokine genesTNFWomenRiskIL10RA
2006
Clinical Experience With Denileukin Diftitox (ONTAK)
Foss F. Clinical Experience With Denileukin Diftitox (ONTAK). Seminars In Oncology 2006, 33: 11-16. PMID: 16516670, DOI: 10.1053/j.seminoncol.2005.12.017.Peer-Reviewed Original ResearchConceptsIL-2 receptorCutaneous T-cell lymphomaT-cell lymphomaDenileukin diftitoxIntermediate affinity IL-2 receptorsHuman IL-2 receptorChronic lymphocytic leukemiaActivated T lymphocytesDiphtheria toxinClinical profileHodgkin's lymphomaHematologic disordersT lymphocytesLymphocytic leukemiaB cellsClinical experienceB lymphocytesLymphomaCytocidal actionNumber of leukemiasDiftitoxHigh affinity formCellular protein synthesisReceptorsLymphocytes
2002
Lymphoma of the Skin
Connors JM, Hsi ED, Foss FM. Lymphoma of the Skin. Hematology 2002, 2002: 263-282. PMID: 12446427, DOI: 10.1182/asheducation-2002.1.263.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsHumansLymphomaLymphoma, B-CellLymphoma, T-Cell, CutaneousSkin NeoplasmsConceptsT-cell lymphomaCutaneous lymphomasNew World Health Organization classification systemCutaneous anaplastic large cell lymphomaWorld Health Organization classification systemPeripheral T-cell lymphomaCutaneous T-cell lymphomaAnaplastic large cell lymphomaCurrent optimal treatmentLarge cell lymphomaB-cell lymphomaMycosis fungoidesSkin lymphomaHodgkin's lymphomaOptimal treatmentStandard treatmentCell lymphomaEffective modalityLymphoma entitiesTreatment approachesLymphomaLymphoma classificationDiseaseSkinTreatment